Wells Fargo analyst Mohit Bansal has maintained their bullish stance on ABBV stock, giving a Buy rating on October 11. Mohit Bansal has given ...

Hillyer, MD, President and CEO of NYBCe, and General Partner and Manager of NYBC Ventures. “With a $50 million commitment, we’ve deployed capital across 15 companies that are delivering breakthrough ...

TEANECK, N.J., Oct. 16, 2024 /CNW/ -- Cognizant (NASDAQ:CTSH) today announced significant enhancements to its Cognizant Neuro ® AI platform, aimed at enabling enterprises to rapidly discover, ...

Gilead Sciences (GILD) ended the recent trading session at $85.83, demonstrating a +0.91% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.76%. Meanwhile, ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

Cognizant and Palo Alto Networks are partnering to deliver AI-driven cybersecurity capabilities and services for enterprises ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

Who is Nirmala Bandrapalli? Nirmala Bandrapalli was born in Hyderabad and came to the US for higher education over 30 years ...

Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target ...